🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03168815
Active, not recruiting Not applicable

Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy

NCT03168815 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2018-01-10
Last updated
2025-05-09

Condition(s) studied

ImmunocompromisedHematologic MalignancyPost Hematopoietic Stem Cell TransplantHypoxiaPulmonary Infiltrates

Investigational drug(s) / intervention(s)

High Flow Nasal Cannula or Low Flow Nasal Cannula

High Flow Nasal Cannula or Low Flow Nasal Cannula: HFNC vs LFNC

Study summary

Pneumonia is a lung infection. Fiberoptic bronchoscopy is a test to diagnose the type of lung infection. While this procedure is being performed, a small amount of oxygen is delivered into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen of the patient may drop and an intervention such as increasing the oxygen flow, or placing the patient on a breathing machine is required. An alternative device called 'Optiflow' can provide high flow oxygen through nasal cannula, and is comfortable for patients. If Optiflow is used during bronchoscopy, it may prevent the blood oxygen from dropping.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients ≥18 years scheduled to undergo FOB (as determined by their medical care team) who are immunocompromised (active hematologic malignancy or post hematopoietic stem cell transplant), and are hypoxic with pulmonary infiltrates. Hypoxia will be defined as requiring supplemental low flow oxygen ≥ 2L/min by nasal cannula to maintain SpO2 \>90%. Exclusion Criteria: 1. requiring supplemental oxygen \> 8L/min by nasal cannula; 2. receiving HFNC before randomization; 3. nasal deformity or packing precluding HFNC use; 4. hypercapnia (PaCO2 \> 60) or respiratory acidosis (pH \<7.25); 5. requiring NIV for over 1 hour or intubated.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mount Sinai Hospital Toronto Ontario

More Mount Sinai Hospital, Canada trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03168815 on ClinicalTrials.gov ↗ ← All trials in Canada